Equities

Rhythm Biosciences Ltd

Rhythm Biosciences Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.056
  • Today's Change-0.002 / -3.45%
  • Shares traded152.05k
  • 1 Year change-87.83%
  • Beta2.3766
Data delayed at least 20 minutes, as of Jul 24 2024 07:10 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Rhythm Biosciences Ltd is an Australia-based medical diagnostics company. The Company is engaged in delivering simple, affordable blood tests for accurate and early detection of cancers. It is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives. The Company has developed ColoSTAT, a blood test for the detection of Colorectal Cancer (CRC). If diagnosed early, colorectal cancer is curable. The ColoSTAT Test-Kit measures five specific protein biomarkers that indicate the likelihood of CRC. The test is an alternative for individuals who are unable or unwilling to participate in current screening programs. It is being updated to meet the IVDR (In vitro diagnostic medical devices regulation) regulatory standards. It is focused on working with likeminded global partners to achieve commercialization and distribution of these simple solutions.

  • Revenue in AUD (TTM)157.67k
  • Net income in AUD-8.63m
  • Incorporated2017
  • Employees--
  • Location
    Rhythm Biosciences LtdBio21 Institute30 Flemington Road, ParkvilleMELBOURNE 3010AustraliaAUS
  • Phone+61 39614-0600
  • Fax+61 39614-0550
  • Websitehttps://www.rhythmbio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Avecho Biotechnology Ltd473.55k-3.44m7.92m29.00--1.24--16.73-0.0016-0.00160.00020.0020.08882.070.5132---64.45-47.08-75.73-55.25-9.2578.67-725.70-156.438.19--0.0267---58.07-19.42-46.71------
Island Pharmaceuticals Ltd10.28k-2.37m8.62m----9.75--838.54-0.026-0.0260.00010.0070.0038--0.0318---88.77---134.02-------23,100.68------0.4433-------8.58------
Bioxyne Ltd8.65m-14.17m10.23m16.00--3.28--1.18-0.0074-0.00740.00440.00151.836.1210.50---302.23-22.07-418.10-28.5038.3045.13-165.04-39.691.50--0.00--1,013.0520.97-292.69---19.86--
BTC Health Ltd16.03k-8.26m12.64m1.00--2.337.66788.57-0.0305-0.03050.000050.01670.0017--0.031---89.67-23.15-91.36-24.64-----51,522.02-2,498.18---0.07870.00---86.04-26.76-1,665.01------
Adalta Ltd3.56m-5.04m14.29m----5.21--4.01-0.0129-0.01290.00920.00460.5491--4.72---77.76-67.77-195.09-103.16-----141.60-160.72---57.860.4533--28.1811.1719.96---7.47--
Patrys Ltd1.70m-5.12m14.40m15.00--2.87--8.50-0.0025-0.00250.00080.00240.1978--0.5828---59.77-43.96-68.99-47.06-----302.26-230.44----0.00---14.4540.52-4.15------
Rhythm Biosciences Ltd157.67k-8.63m14.42m----10.54--91.45-0.0386-0.03860.00070.00550.0263--1.81---144.00-106.11-169.71-125.51-1,899.74-1,210.71-5,473.20-6,642.262.04--0.0304--814.1828.776.55---20.43--
Tissue Repair Ltd457.52k-3.28m14.51m----0.8426--31.72-0.0542-0.05420.00760.28480.0209--7.95---14.96---15.46--98.19---716.30--25.84--0.00------38.95------
Algorae Pharmaceuticals Ltd84.10k-2.25m15.19m----4.19--180.58-0.0015-0.00150.000060.00220.0245--1.79---65.51-46.12-70.91-53.52-----2,678.04-591.05---136.750.00--1,132.26-44.06-7.68------
Medlab Clinical Ltd366.64k-3.94m15.31m14.00------41.77-1.73-1.730.1606-0.30680.1069--5.82---103.72-55.07-240.52-69.7584.7752.86-970.74-335.43---342.19-----28.90-29.8318.55---30.00--
Amplia Therapeutics Ltd4.44m-4.50m16.73m1.00--1.07--3.77-0.0226-0.02260.02220.05720.2647--2.05---26.86-25.13-32.90-27.42-----101.48-206.74----0.122--286.42144.8127.86---6.91--
Chimeric Therapeutics Ltd0.00-11.31m17.52m----1.05-----0.027-0.0270.000.01910.00-------45.96---69.36-------------10.010.1596-------60.40------
Noxopharm Ltd3.90m-12.13m20.46m1.00k--3.11--5.24-0.0415-0.04150.01340.02250.2684--1.643,901.84-83.43-50.96-94.78-62.98-----310.82-191.70---1.470.00--11.3244.0219.34------
BPH Energy Ltd345.67k894.65k20.66m2.00k18.370.8882--59.760.0010.0010.00040.02030.0177--5.97--4.58-6.894.78-7.7256.39--258.50-357.76----0.0043--96.545.21179.13------
Alterity Therapeutics Ltd123.46k-12.28m21.28m11.00--0.6361--172.37-0.005-0.0050.000050.00630.0044--1.5211,223.64-44.20-53.02-53.57-61.96-----9,947.97-40,995.62----0.0143--557.60-39.40-7.47---34.88--
Data as of Jul 24 2024. Currency figures normalised to Rhythm Biosciences Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

3.98%Per cent of shares held by top holders
HolderShares% Held
FIL Investment Management (Hong Kong) Ltd.as of 31 May 202410.06m3.98%
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.